An interventional study of Cyriax Physiotherapy in Low Back Pain, sponsored by Karol Ogurkowski. Completed at 1 site in Poland. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Karol Ogurkowski · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Low Back Pain with a site in Poland — 7 open to participants now, 7 under way, none of them phase 3. Low Back Pain · Poland.
Among the 31 studies in Low Back Pain with a site in Poland, this one is the 10th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2016, is one of 19 with no phase, and was the 31st registered.
2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.
Browse Low Back Pain studies →7 of the 31 studies in Low Back Pain with a site in Poland are open now. Recruiting first, the newest first:
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Sites in Poland
Ages 18–65
University of Rzeszow · Sites in Poland
Ages 30–65
Wroclaw University of Health and Sport Sciences · Sites in Poland
Ages 30–65
Copernicus Memorial Hospital · Sites in Poland
Ages 18+
The Jerzy Kukuczka Academy of Physical Education in Katowice · Sites in Poland
Ages 18–30 · Men only · Healthy volunteers
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 5 · Phase 4 3
First in 2008; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 60 across 2,366 interventional studies indexed under Low Back Pain.
Median enrollment 80 across the 29 interventional studies, 154 across the 2 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 31 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Karol Ogurkowski as lead sponsor.
Karol Ogurkowski has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Low Back Pain with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07675304National Institute of Geriatrics, Rheumatology and Rehabilitation, PolandEvaluation of the Effectiveness and Safety of Mesotherapy in the Treatment of Chronic Low Back Pain Syndrome | 2026-12 |
| NCT06975345Wroclaw University of Health and Sport SciencesEffects of a Protocol of Hip Flexor Stretching on Chronic Mechanical, Non-specific LBP. | 2026-12-31 |
| NCT07463729University of RzeszowEvaluation of Stabilization Training With Biofeedback in Lumbosacral Spine Pain Syndrome | 2027-05-31 |
| NCT07915167The Jerzy Kukuczka Academy of Physical Education in KatowiceThe Influence of Hydration on the Viscoelastic Properties of Soft Tissues, Pain and Mobility of Patients | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Low Back Pain with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study examined the relationship between affective temperament (relatively stable emotional traits) and lower back movement in adults with mechanically provoked low back pain. It also described changes in pain and lower back movement during a two-week Cyriax physiotherapy program. The study was conducted at one rehabilitation clinic in Bydgoszcz, Poland, during 2016-2018 and included 100 adults (73 women and 27 men). All participants received ten individual, in-person physiotherapy sessions of 30 minutes each over two consecutive weeks. There was one treatment group, with no random assignment, comparison group, or blinded outcome assessment. Temperament was assessed before treatment; pain and lower back movement were assessed before and immediately after the program. This is a retrospective registration of a completed study. The study was not prospectively registered. Its exploratory analyses cannot establish that physiotherapy caused any observed changes.
This retrospective record is based on the available study documentation and author-review manuscript and supplement (V9). The study was an uncontrolled, nonrandomized, single-center interventional study at the Rehabilitation Clinic of Dr Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Poland. The Bioethics Committee of Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, approved the protocol on 24 May 2016 (KB379/2016). Written informed consent was obtained before enrollment. During preparation of this retrospective registration on 9 November 2026, the investigator supplied 1 June 2016 as the study start date and confirmed 31 December 2018 as the date of the last participant measurements. Primary and overall study completion are entered as 31 December 2018. The earlier preprint (doi:10.20944/preprints202507.2277.v1) described a period beginning on 24 May 2016, which is the ethics approval date; the structured study start date follows the investigator clarification. CYRIAX is an administrative identifier assigned when preparing this retrospective record.
Baseline assessments included the Polish TEMPS-A, a 21-item Beck Depression Inventory, and a 0-10 pain rating. Lumbar mobility was measured in degrees with the ultrasonic TECHNOMEX ZEBRIS BACK WS system in six directions: flexion, extension, left and right rotation, and left and right lateral flexion. Pain and mobility were reassessed immediately after the two-week intervention. TEMPS-A and Beck scores were baseline characteristics, not repeated treatment outcomes. The exact Beck edition, the physical pain-scale format and recall interval, and some mobility measurement details could not be verified.
The Official Title uses the title of the V9 manuscript for this retrospective registration; it is not asserted to be a verified transcription of the original ethics protocol title. The original primary versus secondary outcome hierarchy has not been verified from the contemporaneous protocol. For this retrospective registration, the six directional lumbar mobility measurements are designated primary and the 0-10 pain rating secondary, based on the research focus in the available manuscript. These designations were made after study completion and knowledge of the results, not before enrollment. No prospectively specified hierarchy or statistical analysis plan is asserted by this retrospective record. The current central analysis examines five baseline temperament dimensions against six movement directions at two assessments. The multiplicity adjustments, conditional TEMPS-A rescoring, and additional covariate-adjusted sensitivity analyses are retrospective; the covariate-adjusted models were added post hoc after editorial review. They are not preregistered confirmatory or validated prediction analyses.
The database contains 110 TEMPS-A columns for every participant, although the published form has 110 applicable items for women and 109 for men. Column 84 has an affirmative value in five male records. Whether column 84 maps to the original women-only questionnaire item has not been verified against completed forms. Sex-specific rescoring is conditional on this unresolved mapping; this inconsistency does not prove that men answered the women-only item.
The dissertation listed rheumatic disease among exclusion criteria, but the diagnostic table includes two participants with ankylosing spondylitis. This discrepancy remains unresolved. No criterion or participant was retrospectively removed to resolve it.
Individual posttreatment pain ratings, screening counts and reasons for pre-enrollment exclusion were not recoverable. No a priori sample-size calculation, validated disability outcome, long-term follow-up, or systematic adverse-event recording was available. Absence of systematic adverse-event records must not be interpreted as absence of adverse events.
The earlier preprint lists additional exclusions (mandatory military service and a professional relationship with the author) that are not stated in the V9 eligibility summary. The original eligibility documentation is needed to reconcile these source differences; these criteria have not been silently added to or removed from the reconstructed eligibility list.
Inclusion Criteria:
Exclusion Criteria (as reported in the available study documentation):
Unresolved source discrepancy: The dissertation also listed rheumatic disease among exclusions, but the diagnostic table included two participants with ankylosing spondylitis. The original criterion and its application require verification against contemporaneous records. This retrospective description does not remove that criterion or exclude any participant to resolve the discrepancy. Participants were not selected on the basis of psychiatric diagnosis; no structured psychiatric diagnostic assessment was documented.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All 100 participants received ten individual, in-person Cyriax physiotherapy sessions, each scheduled for 30 minutes on weekdays over two consecutive weeks. Techniques were selected individually following functional examination and reassessment. A physiotherapist with formal Cyriax training and neurological and orthopedic rehabilitation experience delivered treatment. Home recommendations included prone rest and lumbar extension positioning. There was no control group, random allocation, or blinded outcome assessment.
Other: Cyriax Physiotherapy
Ten individual, in-person sessions, 30 minutes each on weekdays over two consecutive weeks. A trained physiotherapist individualized techniques after functional examination and reassessment. Available procedures included soft-tissue mobilization; rotational manipulation (stretch); rotational manipulation with leverage (leg over); combined rotation and lateral flexion (Dallison); rhythmic central extension pressure; unilateral extension pressure; and correction of lateral deviation using rotation, lateral flexion, or extension. Manipulative procedures involved preliminary traction, a technique-specific controlled movement, and immediate reassessment. Not every technique was applied to every participant. Home advice comprised prone rest and lumbar extension positioning. Exact technique exposure, home-position dosage, and adherence were not sufficiently documented.
Lumbar Flexion Range of Motion
Lumbar flexion angle in degrees, measured with the ultrasonic TECHNOMEX ZEBRIS BACK WS system. Absolute magnitudes of recorded directional angles are used. Measurements at each assessment are examined in relation to baseline TEMPS-A dimensions; within-person change is exploratory. Larger angles indicate greater measured mobility and are not a validated threshold of clinical recovery. Designated as a primary measure retrospectively for this registration, based on the manuscript research question; the original prespecified outcome hierarchy could not be verified.
Time frame: Baseline (before the first session) and immediately after the two-week program (after session 10).
Lumbar Extension Range of Motion
Lumbar extension angle in degrees, measured with the ultrasonic TECHNOMEX ZEBRIS BACK WS system. Absolute magnitudes of recorded directional angles are used. Measurements at each assessment are examined in relation to baseline TEMPS-A dimensions; within-person change is exploratory. Larger angles indicate greater measured mobility and are not a validated threshold of clinical recovery. Designated as a primary measure retrospectively for this registration, based on the manuscript research question; the original prespecified outcome hierarchy could not be verified.
Time frame: Baseline (before the first session) and immediately after the two-week program (after session 10).
Lumbar Left Rotation Range of Motion
Lumbar left rotation angle in degrees, measured with the ultrasonic TECHNOMEX ZEBRIS BACK WS system. Absolute magnitudes of recorded directional angles are used. Measurements at each assessment are examined in relation to baseline TEMPS-A dimensions; within-person change is exploratory. Larger angles indicate greater measured mobility and are not a validated threshold of clinical recovery. Designated as a primary measure retrospectively for this registration, based on the manuscript research question; the original prespecified outcome hierarchy could not be verified.
Time frame: Baseline (before the first session) and immediately after the two-week program (after session 10).
Lumbar Right Rotation Range of Motion
Lumbar right rotation angle in degrees, measured with the ultrasonic TECHNOMEX ZEBRIS BACK WS system. Absolute magnitudes of recorded directional angles are used. Measurements at each assessment are examined in relation to baseline TEMPS-A dimensions; within-person change is exploratory. Larger angles indicate greater measured mobility and are not a validated threshold of clinical recovery. Designated as a primary measure retrospectively for this registration, based on the manuscript research question; the original prespecified outcome hierarchy could not be verified.
Time frame: Baseline (before the first session) and immediately after the two-week program (after session 10).
Lumbar Left Lateral Flexion Range of Motion
Lumbar left lateral flexion angle in degrees, measured with the ultrasonic TECHNOMEX ZEBRIS BACK WS system. Absolute magnitudes of recorded directional angles are used. Measurements at each assessment are examined in relation to baseline TEMPS-A dimensions; within-person change is exploratory. Larger angles indicate greater measured mobility and are not a validated threshold of clinical recovery. Designated as a primary measure retrospectively for this registration, based on the manuscript research question; the original prespecified outcome hierarchy could not be verified.
Time frame: Baseline (before the first session) and immediately after the two-week program (after session 10).
Lumbar Right Lateral Flexion Range of Motion
Lumbar right lateral flexion angle in degrees, measured with the ultrasonic TECHNOMEX ZEBRIS BACK WS system. Absolute magnitudes of recorded directional angles are used. Measurements at each assessment are examined in relation to baseline TEMPS-A dimensions; within-person change is exploratory. Larger angles indicate greater measured mobility and are not a validated threshold of clinical recovery. Designated as a primary measure retrospectively for this registration, based on the manuscript research question; the original prespecified outcome hierarchy could not be verified.
Time frame: Baseline (before the first session) and immediately after the two-week program (after session 10).
Low Back Pain Intensity
Pain intensity recorded on a 0-10 scale, from 0 (no pain) to 10 (strongest pain); higher scores indicate more pain. The source called the instrument a visual analog scale but described numbered ratings; the original physical format and recall interval could not be verified. Pain was assessed before and after treatment. Archived group summaries and counts of decreases, unchanged ratings, and increases are available, but individual final pain ratings were not recovered. Any decrease is not a prespecified clinically important improvement threshold. Designated secondary retrospectively for this registration; original prespecification could not be verified.
Time frame: Baseline (before the first session) and immediately after the two-week program (after session 10).
Ran from Jun 2016 to primary completion in Dec 2018, 30 months.
Of 1,233 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 30 months is above that.
Counting every sponsor, half of 1,288 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.